Hypermarcas (OTCMKTS:HYPMY) Sees Large Decrease in Short Interest

Hypermarcas (OTCMKTS:HYPMY) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 2,343 shares, a decrease of 62.4% from the August 31st total of 6,225 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average trading volume of 12,182 shares, the days-to-cover ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group upgraded shares of Hypermarcas to a “strong-buy” rating in a research note on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy”.

Hypermarcas Stock Down 5.4%

Shares of OTCMKTS:HYPMY traded down $0.25 during trading on Monday, hitting $4.40. The company’s stock had a trading volume of 303 shares, compared to its average volume of 19,637. The company has a market capitalization of $3.10 billion, a PE ratio of 8.80 and a beta of 0.71. Hypermarcas has a fifty-two week low of $3.71 and a fifty-two week high of $5.50. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.26 and a current ratio of 1.86. The stock’s 50-day moving average price is $4.28 and its two-hundred day moving average price is $4.32.

Hypermarcas (OTCMKTS:HYPMY) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. As a group, sell-side analysts expect that Hypermarcas will post 0.53 EPS for the current year.

Hypermarcas Company Profile

Hypermarcas SA was a Brazilian consumer health and pharmaceutical company that developed, manufactured and marketed branded products for healthcare, personal care and consumer markets. Its portfolio historically included over-the-counter medicines, prescription products, vitamins, toiletries, cosmetics and other household or personal-care brands.

The company expanded through acquisitions and operated primarily in Brazil, building a broad portfolio of locally recognized brands. In the mid-2010s, Hypermarcas began divesting its non-pharmaceutical businesses to concentrate on healthcare and medicines.